Use of soluble guanylate cyclase activators for treating reperfusion damage

Details for Australian Patent Application No. 2006286896 (hide)

Owner Bayer HealthCare AG

Inventors Weimann, Gerrit; Krahn, Thomas; Stasch, Johannes-Peter; Thielemann, Wolfgang

Agent Davies Collison Cave

Pub. Number AU-A-2006286896

PCT Pub. Number WO2007/025595

Priority 10 2005 031 576.3 06.07.05 DE

Filing date 6 July 2006

Wipo publication date 8 March 2007

International Classifications

A61K 31/192 (2006.01)

A61K 31/195 (2006.01)

A61K 31/381 (2006.01) - having five-membered rings

A61K 31/42 (2006.01) - Oxazoles

A61K 31/422 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/5377 (2006.01)

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

31 January 2008 PCT application entered the National Phase

  PCT publication WO2007/025595 Priority application(s): WO2007/025595

14 May 2009 Assignment before Grant

  Bayer HealthCare AG The application has been assigned to Bayer Schering Pharma Aktiengesellschaft

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006286897-Pyrazolo [3 , 4-d] azepine derivatives as histamine H3 antagonists

2006286894-Case for accommodating a medicament pack, and use thereof